AI Article Synopsis
- The study tested Cefazedone, a new antibiotic, on 40 patients with skin infections, showing a high success rate of 92% in treating conditions like Erysipelas and Pyodermia.
- Most patients received an average of 9 days of treatment with doses primarily at 2X1 g i.v., leading to successful elimination of pathogens like Streptococci and St. aureus.
- Minor side effects were reported in two patients due to rapid injection, but overall, Cefazedone was well-tolerated both locally and systemically.
Article Abstract
The efficacy and tolerance of Cefazedone, a new Cephalosporin derivate, were investigated in an open clinical trial on 40 patients with bacteriological skin infections. Patients with Erysipelas, impetiginized dermatoses and Pyodermia were treated during an average period of 9 days mainly with a dosage of 2X1 g i.v., in some cases with 2X2 g i.v. daily. The success of the treatment was good--very good in 92% of the cases. All pathogens isolated before treatment (Streptococci, St. aureus, E. coli) were eliminated after treatment. 2 patients showed transitory incompatibility reactions due to too rapid injections. The local and systemic tolerance were excellent in all other cases. 1 hour after i.v. injection of 1 g Cefazedone to 20 patients the mean concentration in the serum was 51 micrograms per ml and in the skin-tissue 10.6 micrograms/g.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Navigating Bowel Preparation for Colonoscopy: A Comprehensive Overview.
J Clin Gastroenterol
December 2024
Department of Medicine.
Colorectal cancer (CRC) is the third most common cancer in the United States. Early detection through colonoscopy significantly improves survival rates. Detecting colon polyps depends on the quality of bowel preparation.
View Article and Find Full Text PDFBackground: There is continuous demand for safe, effective cosmetic ingredients to treat the signs of aging skin, including fine lines, wrinkles, brown spots, discoloration, laxity, and sagging. While there are a plethora of cosmeceutical peptides, few combine anti-aging and anti-inflammatory benefits with small size.
Methods: Preclinical and clinical studies evaluated the anti-inflammatory properties, anti-aging benefits, and tolerability of acetyl dipeptide-31 amide (AP31), a novel, small, anti-aging micropeptide, to understand its impact as a multifaceted, cosmetic, anti-aging, and anti-inflammaging ingredient.
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder.
J Child Adolesc Psychopharmacol
January 2025
Director of Co-Founder and Founder of Schizophrenia Society, University of Cincinnati, Cincinnati, Ohio, USA.
Bipolar disorder often begins in adolescence or early adulthood, characterized by recurrent manic episodes that can lead to neurodegenerative brain changes and functional decline. While several oral second-generation antipsychotics are Food and Drug Administration (FDA)-approved for mania, adherence to maintenance treatment is frequently poor due to factors such as anosognosia, cognitive dysfunction, impulsivity, side effects aversion, and substance use. Long-acting injectable (LAI) antipsychotics, approved for adults with bipolar mania or schizoaffective disorder (bipolar type), offer a potential solution for adolescents with similar conditions.
View Article and Find Full Text PDFBackground: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!